PatrĂ­cia Silva, PhD,  director of science content—

PatrĂ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĂ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by PatrĂ­cia Silva

Bayer Presenting New Data on Riociguat as PAH and CTEPH Treatments at ATS 2016

Bayer is presenting six abstracts on studies investigating riociguat for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) at the 2016 American Thoracic Society (ATS) International Conference now taking place in San Francisco, California. Riociguat (BAY 63-2521, trade name Adempas) is a stimulator of soluble guanylate cyclase (sGC). It is indicated for the treatment…

Galectin to Present Data on Potential PAH Treatment, a Galectin-3 Inhibitor, at ATS 2016

Galectin Therapeutics, Inc., will present an abstract, a collaboration with researchers at Augusta University titled “Galectin-3 Mediates Vascular Remodeling in Pulmonary Arterial Hypertension,” at the 2016 International Conference of the American Thoracic Society (ATS) being held May 13–18 in San Francisco. The study, undertaken in the labs of Drs. Scott Barman and…

Balloon Angioplasty Seen to Benefit People with Inoperable CTEPH and Other Conditions, Too

Balloon pulmonary angioplasty (BPA) appears to be of multiple benefit to patients with chronic thromboembolic pulmonary hypertension (CTEPH), both in terms of hemodynamics and in other systemic disorders like glycemic control and kidney disease, according to a study published in the journal Circulation, titled “Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients…

Pulmonary Fibrosis Foundation Enrolls 1st Person in PFF Patient Registry, a Research Tool

The Pulmonary Fibrosis Foundation (PFF) announced it has enrolled its first pulmonary fibrosis (PF) patient in the newly launched PFF Patient Registry, a collaborative effort involving patients, researchers, and healthcare providers that will gather data to advance PF research and improve patients’ quality of life. Enrollment takes place at participating PFF Care Center Network (CCN) sites across the…

Pulmonary Hypertension Risk in People with Pulmonary Embolisms Often Overlooked, Study Finds

Results from a retrospective study based on a claims database of U.S. patients with pulmonary embolism indicated that physicians are failing to recognize and diagnose thousands of cases of a serious lung disease, chronic thromboembolic pulmonary hypertension (CTEPH). The study, “Monitoring for Pulmonary Hypertension Following Pulmonary Embolism: The INFORM…